Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia

Journal of Clinical Oncology

Volumn 30, Issue 3, 2012, Pages 223-224

  Cortes, Jorge E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG MEGADOSE; EDITORIAL; EVENT FREE SURVIVAL; HUMAN; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84856004351     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.6655     Document Type: Editorial

References (12)

1. Iacobucci I, Rosti G, Amabile M, et al: Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 24:454-459, 2006 (Pubitemid 46630464)
2. Cortes JE, Kantarjian HM, Goldberg SL, et al: High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses. J Clin Oncol 27:4754-4759, 2009
3. Hughes T, Branford S: Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 20:29-41, 2006 (Pubitemid 43106716)
4. Quinta'́s-Cardama A, Kantarjian H, Jones D, et al: Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113:6315-6321, 2009
5. Marin D, Ibrahim AR, Lucas C, et al: Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30:232-238, 2012
6. Ross DM, Branford S, Moore S, et al: Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia 20:664-670, 2006
7. Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270, 2010
8. Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259, 2010
9. Jabbour E, Kantarjian H, O'Brien S, et al: The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 118:4541-4546, 2011
10. Yeung DT, Osborn M, White D, et al: Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: Interim results from the TIDEL-II trial. Blood 116, 2010 (abstr 209)
11. Craddock C, Szydlo RM, Klein JP, et al: Estimating leukemia-free survival after allografting for chronic myeloid leukemia: A new method that takes into account patients who relapse and are restored to complete remission. Blood 96:86-90, 2000 (Pubitemid 30456455)
12. Al-Kali A, Kantarjian H, Shan J, et al: Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 117:327-335, 2011